EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

Priya Rastogi iD, Hanna Bandos, Peter C Lucas iD, Laura J van 't Veer iD, Jia-Perng J Wei, Charles E Geyer iD, Louis Fehrenbacher iD, Stephen K L Chia iD, Adam M Brufsky iD, Janice M Walshe iD, Gamini S Soori, Shaker R Dakhil und 6 weitere

Journal of Clinical Oncology · 20.10.2024 · 42 (30) · 3561-3569

DOI: 10.1200/jco.23.01995 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.10.2024. Verfasst von Priya Rastogi und 17 weiteren Autor:innen. Beteiligte Einrichtung: UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA. Hauptthemen laut MEDLINE: Breast Neoplasms, Letrozole, Genetic Testing, Genes, Neoplasm. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE MammaPrint (MP) determines distant metastatic risk and may improve patient selection for extended endocrine therapy (EET). This study examined MP in predicting extended letrozole therapy (ELT) benefit in patients with early-stage breast cancer (BC) from the NSABP B-42 trial. PATIENTS AND METHODS MP was tested in 1,866 patients randomly assigned to receive ELT or placebo. The primary end point was distant recurrence (DR). Secondary end points were disease-free survival (DFS) and BC-free interval (BCFI). Tumors were classified as MP high risk (MP-HR) or low risk (MP-LR). MP-LR tumors were further classified as ultralow risk (MP-UL) or low non-ultralow risk (MP-LNUL). RESULTS There was no statistically significant difference in ELT benefit on DR between MP-HR and MP-LR (interaction P = .38). MP-LR tumors (n = 1,160) exhibited a statistically significant 10-year benefit of 3.7% for DR (hazard ratio [HR], 0.43 [95% CI, 0.25 to 0.74]; P = .002), whereas MP-HR tumors (n = 706) exhibited a nonsignificant 2.4% benefit (HR, 0.65 [95% CI, 0.34 to 1.24]; P = .19). The 10-year ELT benefit was significant for DFS (7.8%) and BCFI (7.0%) for MP-LR tumors, whereas MP-HR tumors did not significantly benefit (interaction DFS: P = .015, BCFI: P = .006). In exploratory analysis, the 10-year ELT benefit was significant and more pronounced in MP-LNUL (n = 908) tumors: 4.0% for DR, 9.5% for DFS, and 7.9% for BCFI; the benefit in MP-UL (n = 252) tumors was not significant: 3% for DR, 1.8% for DFS, and 4.1% for BCFI. CONCLUSION The primary hypothesis of predictive ability of MP on DR was not confirmed. However, the secondary outcomes demonstrated MP was predictive of ELT response and identified a subset of patients with early-stage hormone receptor–positive BC (MP-LR) with improved outcomes from ELT. These data could have important clinical implications in patient selection beyond clinical risk assessment for EET.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsLetrozoleGenetic TestingGenes, NeoplasmAdultAgedFemaleHumansMiddle AgedAntineoplastic AgentsAromatase InhibitorsDisease-Free SurvivalGene Expression ProfilingNitrilesPredictive Value of TestsRisk AssessmentTriazoles

Substanzen

Antineoplastic AgentsAromatase InhibitorsLetrozoleNitrilesTriazoles

Autor:innen und Institutionen

  • UPMC Hillman Cancer Center, University of Pittsburgh School of Medicine, Pittsburgh, PA.
  • Magee-Women's Hospital, Pittsburgh, PA.
  • NRG Oncology SDMC, Pittsburgh, PA.
  • University of Pittsburgh, School of Public Health, Pittsburgh, PA.
  • Agendia, Inc, Irvine, CA.
  • Kaiser Permanente Oncology Clinical Trials Northern CA, Novato, CA.

ORCID-Profile: Priya Rastogi, Peter C Lucas, Laura J van 't Veer, Charles E Geyer, Louis Fehrenbacher, Stephen K L Chia, Adam M Brufsky, Janice M Walshe, Soonmyung Paik, Sandra M Swain, Andrea R Menicucci, M William Audeh, Norman Wolmark, Eleftherios P Mamounas

Förderung

  • NCI NIH HHS

Zitieren

APA

Rastogi, P., Bandos, H., Lucas, P. C., van 't Veer, L. J., Wei, J. J., Geyer, C. E., Fehrenbacher, L., Chia, S. K. L., Brufsky, A. M., Walshe, J. M., Soori, G. S., Dakhil, S. R., Paik, S., Swain, S. M., Menicucci, A. R., Audeh, M. W., Wolmark, N., & Mamounas, E. P. (2024). Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. Journal of Clinical Oncology, 42(30), 3561-3569. https://doi.org/10.1200/jco.23.01995

Vancouver

Rastogi P, Bandos H, Lucas PC, van 't Veer LJ, Wei JJ, Geyer CE, et al. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. Journal of Clinical Oncology. 2024;42(30):3561-3569. doi:10.1200/jco.23.01995

BibTeX
@article{Rastogi2024,
  author = {Rastogi, Priya and Bandos, Hanna and Lucas, Peter C and van 't Veer, Laura J and Wei, Jia-Perng J and Geyer, Charles E and Fehrenbacher, Louis and Chia, Stephen K L and Brufsky, Adam M and Walshe, Janice M and Soori, Gamini S and Dakhil, Shaker R and Paik, Soonmyung and Swain, Sandra M and Menicucci, Andrea R and Audeh, M William and Wolmark, Norman and Mamounas, Eleftherios P},
  title = {Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {30},
  pages = {3561--3569},
  doi = {10.1200/jco.23.01995}
}
Kostenlos starten →